Porton Pharma Solutions Ltd. (SHE:300363)
China flag China · Delayed Price · Currency is CNY
21.77
+0.22 (1.02%)
Apr 8, 2026, 3:04 PM CST

Porton Pharma Solutions Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
11,75912,5538,60213,73522,30548,697
Market Cap Growth
28.71%45.93%-37.37%-38.42%-54.20%145.68%
Enterprise Value
12,00613,1069,40313,24920,59848,168
Last Close Price
21.7723.2415.7724.3438.2483.52
PE Ratio
120.94130.30-51.4711.1292.95
Forward PE
58.8468.7654.1427.0712.6371.85
PS Ratio
3.443.672.863.753.1715.68
PB Ratio
2.142.281.592.253.4511.63
P/TBV Ratio
2.452.611.852.624.1313.64
P/FCF Ratio
25.3227.03--16.03-
P/OCF Ratio
15.5316.5821.2121.838.70101.42
PEG Ratio
-0.760.760.760.760.76
EV/Sales Ratio
3.513.833.123.612.9315.51
EV/EBITDA Ratio
20.4322.9998.0522.828.4066.91
EV/EBIT Ratio
56.8962.11-45.399.2986.65
EV/FCF Ratio
25.8528.22--14.81-
Debt / Equity Ratio
0.280.280.360.320.140.18
Debt / EBITDA Ratio
2.572.5711.403.080.370.99
Debt / FCF Ratio
3.253.25--0.66-
Net Debt / Equity Ratio
0.020.020.090.00-0.30-0.11
Net Debt / EBITDA Ratio
0.180.185.020.01-0.79-0.66
Net Debt / FCF Ratio
0.220.22-5.66-0.01-1.381.60
Asset Turnover
0.390.390.330.380.840.56
Inventory Turnover
3.113.113.102.764.103.11
Quick Ratio
1.251.251.371.941.471.12
Current Ratio
1.821.821.902.631.811.52
Return on Equity (ROE)
0.56%0.56%-6.36%2.79%36.34%12.55%
Return on Assets (ROA)
1.52%1.52%-1.54%1.87%16.59%6.28%
Return on Invested Capital (ROIC)
1.35%1.35%-3.73%3.90%46.32%15.82%
Return on Capital Employed (ROCE)
3.10%3.10%-3.20%3.70%31.10%12.50%
Earnings Yield
0.82%0.77%-3.35%1.94%8.99%1.08%
FCF Yield
3.95%3.70%-0.99%-3.65%6.24%-0.61%
Dividend Yield
---2.00%2.89%0.23%
Payout Ratio
31.25%31.25%-234.79%6.44%15.80%
Buyback Yield / Dilution
1.42%1.42%0.31%-0.21%-0.62%0.11%
Total Shareholder Return
1.42%1.42%0.31%1.79%2.27%0.34%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.